FT-023

FT-023 is a preclinical **rAAV gene therapy** candidate from **Fronterra** being developed for retinal vascular diseases including **neovascular age-related macular degeneration**, **diabetic macular edema**, and **diabetic retinopathy**. Public pipeline information identifies it as an ophthalmic recombinant adeno-associated virus program, but the **specific transgene, molecular target, and detailed mechanism of action have not been disclosed**. Based on the disclosed modality and disease focus, FT-023 is intended as a gene therapy approach for chronic retinal disease, but its exact anti-angiogenic or vascular-stabilizing design remains undisclosed.